Nonpeptidic HIV protease inhibitors: 6-alkyl-5, 6-dihydropyran-2-ones possessing achiral 3-(4-amino/carboxamide-2-t-butyl, 5-methylphenyl thio) moiety: Antiviral activities and pharmacokinetic properties
J. V. N. Vara Prasad(Pfizer (United States)), Joanne Brodfuehrer(Pfizer (United States)), Fred E. Boyer(Warde Medical Laboratory), Larry J. Markoski(Pfizer (United States)), Christopher Gajda(Pfizer (United States)), K. R. Krishna Iyer(University of Michigan), Susan E. Hagen(Pfizer (United States)), Elizabeth A. Lunney(Pfizer (United States)), Edmund L. Ellsworth(Pfizer (United States)), Peter J. Tummino(Ensemble Therapeutics (United States)), James M. Saunders(Pfizer (United States)), Carolyn Nouhan(Pfizer (United States)), Michael Sinz(Rutgers, The State University of New Jersey), Donna Ferguson(Pfizer (United States)), Donald Hupe(Pfizer (United States)), Steven VanderRoest(Pfizer (United States)), Bradley D. Tait(Pfizer (United States)), Stephen J. Gracheck(Pfizer (United States)), John M. Domagala(Pfizer (United States)), Tod P. Holler(Pfizer (United States))
Cited by 8
Related Papers
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
|Chemical Research in Toxicology|1998|312
Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole
|Oncogene|2006|211
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
|Antimicrobial Agents and Chemotherapy|2012|186
Pharmacokinetic Drug Interactions Involving 17??-Ethinylestradiol
|Clinical Pharmacokinetics|2007|174